# US 2016/0250323 A1 · Particles Comprising a Shell with RNA

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250323 A1
- Document ID: US20160250323A1
- Status: Published application
- Kind: A1
- Application number: 15/023,052
- Filed: 2013-09-26
- Published: 2016-09-01
- Earliest claimed: 2013-09-26
- Assignees: BioNTech RNA Pharmaceuticals GmbH; Tron—Translationale Onkologie An Der Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Gemeinnuzige GmbH
- Applicants: Biontech AG; Tron - Translationale Onkologie An Der UniversitäT Smedizin Der Johannes Gutenberg-UniversitäT Mainz; UniversitäTsmedizin Der Johannes Gutenberg-UniversitäT Mainz
- Inventors: Ugur Sahin; Heinrich Haas; Sebastian Kreiter; Yves Hüsemann; Mustafa Diken; Kerstin Reuter; Hossam Hefesha
- Web page: https://patentgrep.com/patent/US20160250323A1

## CPC

- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 9/1277: Preparation processes; Proliposomes
- A61K 9/5073: {having two or more different coatings optionally including drug-containing subcoatings}
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 39/0011: {Cancer antigens}
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/55511: {Organic adjuvants}
- A61K 2039/55516: {Proteins; Peptides}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- A61K 2039/572: {cytotoxic response}
- C12N 2810/10: Vectors comprising a non-peptidic targeting moiety
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to RNA decorated particles such as RNA decorated lipid particles, preferably to RNA decorated liposomes. Further, the present invention relates to a pharmaceutical composition comprising RNA decorated particles such as RNA decorated lipid particles, preferably RNA decorated liposomes. Said pharmaceutical composition is useful for inducing an immune response. It is also useful in a prophylactic and/or therapeutic treatment of a disease involving an antigen. Furthermore, the present invention relates to a method for producing the RNA decorated particles such as RNA decorated lipid particles, preferably RNA decorated liposomes.

## Claims

### Claim 1

A particle comprising:
(i) a vesicular core,
(ii) at least one therapeutically effective compound encapsulated within the vesicular core, and
(iii) RNA forming a hydrophilic shell on at least a portion of the vesicular core.

### Claim 2 (depends on 1)

The particle of claim 1, wherein the RNA is pharmaceutically active or encodes at least one pharmaceutically active peptide or protein.

### Claim 3 (depends on 1, 2)

The particle of claim 1 or 2, wherein the RNA encodes at least one antigen.

### Claim 4 (depends on 3)

The particle of claim 3, wherein the antigen is a disease-associated antigen or elicits an immune response against a disease-associated antigen or cells expressing a disease-associated antigen.

### Claim 5 (depends on 1, 2, 3, 4)

The particle of any one of claims 1 to 4, wherein the RNA is exposed to surrounding medium.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The particle of any one of claims 1 to 5, wherein the RNA covers the entire surface of the vesicular core or a portion thereof.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The particle of any one of claims 1 to 6, wherein the therapeutically effective compound is a water-soluble compound.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The particle of any one of claims 1 to 7, wherein the therapeutically effective compound is a small molecule compound.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The particle of any one of claims 1 to 8, wherein the therapeutically effective compound is useful in immunotherapy.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The particle of any one of claims 1 to 9, wherein the therapeutically effective compound is an agent stimulating γδ T cells, preferably Vγ9Vδ2 T cells.

### Claim 11 (depends on 10)

The particle of claim 10, wherein the agent stimulating γδ T cells is a bisphosphonate, preferably a nitrogen-containing bisphosphonate (aminobisphosphonate).

### Claim 12 (depends on 10, 11)

The particle of claim 10 or 11, wherein the agent stimulating γδ T cells is selected from the group consisting of zoledronic acid, clodronic acid, ibandronic acid, pamidronic acid, risedronic acid, minodronic acid, olpadronic acid, alendronic acid, incadronic acid and salts thereof.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The particle of any one of claims 1 to 12, wherein the vesicular core is positively charged.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The particle of any one of claims 1 to 13, wherein the vesicular core is a polymer vesicular core, a protein vesicular core or a lipid vesicular core, preferably a lipid vesicular core.

### Claim 15 (depends on 14)

The particle of claim 14, wherein the lipid vesicular core comprises a lipid bilayer.

### Claim 16 (depends on 14, 15)

The particle of claim 14 or 15, wherein the lipid vesicular core comprises a liposome.

### Claim 17 (depends on 14, 15, 16)

The particle of any one of claims 14 to 16, wherein the lipid vesicular core comprises at least one cationic lipid.

### Claim 18 (depends on 17)

The particle of claim 17, wherein the positive charges are contributed by the at least one cationic lipid and the negative charges are contributed by the RNA.

### Claim 19 (depends on 14, 15, 16, 17, 18)

The particle of any one of claims 14 to 18, wherein the lipid vesicular core comprises at least one helper lipid.

### Claim 20 (depends on 19)

The particle of claim 19, wherein the helper lipid is a neutral lipid or negatively charged lipid.

### Claim 21 (depends on 17, 18, 19, 20)

The particle of any one of claims 17 to 20, wherein the at least one cationic lipid comprises 1,2-dimyristoyl-sn-glycero-3-ethylphosphocholine (DMEPC), 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA) and/or 1,2-dioleoyl-3-trimethylammonium propane (DOTAP).

### Claim 22 (depends on 19, 20, 21)

The particle of any one of claims 19 to 21, wherein the at least one helper lipid comprises 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine (DOPE), cholesterol (Chol), 1-palmitoyl-2-oleoyl-sn-glycero-3phosphocholin (POPC) and/or 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC).

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The particle of any one of claims 1 to 22, wherein the particle has an average diameter in the range of from about 50 nm to about 1000 nm.

### Claim 24 (depends on 23)

The particle of claim 23, wherein the particle has an average diameter
(i) in the range of from about 50 nm to about 400 nm, preferably from about 50 nm to about 200 nm, or
(ii) in the range of from about 200 nm to about 1000 nm, preferably from about 200 nm to about 800 nm, more preferably from about 300 nm to about 600 nm.

### Claim 25 (depends on 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The particle of any one of claims 14 to 24, wherein the lipid vesicular core having the therapeutically effective compound encapsulated therein is obtainable by reverse phase evaporation technique or ethanol injection technique.

### Claim 26 (depends on 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The particle of any one of claims 14 to 25, wherein the particle is obtainable by addition of the RNA to a lipid vesicular core having the therapeutically effective compound encapsulated therein.

### Claim 27 (depends on 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The particle of any one of claims 14 to 26, wherein the particle is obtainable by a process comprising a step of extruding and/or a step of lyophilizing the particle.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

A pharmaceutical composition comprising particles as set forth in any one of claims 1 to 27.

### Claim 29 (depends on 28)

The pharmaceutical composition of claim 28, wherein, after systemic administration of the particles, at least a portion of the RNA and at least a portion of the therapeutically effective compound are delivered to a target cell, preferably to the same target cell.

### Claim 30 (depends on 29)

The pharmaceutical composition of claim 29, wherein the target cell is a spleen cell, preferably an antigen presenting cell, more preferably a professional antigen presenting cell, more preferably a dendritic cell.

### Claim 31 (depends on 28, 29, 30)

The pharmaceutical composition of any one of claims 28 to 30, wherein, after systemic administration of the particles, RNA accumulation and/or RNA expression in the spleen occurs.

### Claim 32 (depends on 28, 29, 30, 31)

The pharmaceutical composition of any one of claims 28 to 31, wherein, after systemic administration of the particles, no or essentially no RNA accumulation and/or RNA expression in the lung and/or liver occurs.

### Claim 33 (depends on 28, 29, 30, 31, 32)

The pharmaceutical composition of any one of claims 28 to 32, wherein, after systemic administration of the particles, RNA accumulation and/or RNA expression in the spleen is at least 5-fold the amount of RNA accumulation and/or RNA expression in the lung.

### Claim 34 (depends on 28, 29, 30, 31, 32, 33)

The pharmaceutical composition of any one of claims 28 to 33, wherein, after systemic administration of the particles, RNA accumulation and/or RNA expression in antigen presenting cells, preferably professional antigen presenting cells in the spleen occurs.

### Claim 35 (depends on 34)

The pharmaceutical composition of claim 34, wherein the antigen presenting cells are dendritic cells and/or macrophages.

### Claim 36 (depends on 29, 30, 31, 32, 33, 34, 35)

The pharmaceutical composition of any one of claims 29 to 35, wherein systemic administration is by parenteral administration, preferably by intravenous administration, subcutaneous administration, intradermal administration or intraarterial administration.

### Claim 37 (depends on 28, 29, 30, 31, 32, 33, 34, 35, 36)

The pharmaceutical composition of any one of claims 28 to 36, wherein the composition further comprises one or more pharmaceutically acceptable carriers, diluents and/or excipients.

### Claim 38 (depends on 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The pharmaceutical composition of any one of claims 28 to 37, wherein the composition further comprises at least one adjuvant.

### Claim 39 (depends on 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The pharmaceutical composition of any one of claims 28 to 38, wherein the composition is formulated for systemic administration.

### Claim 40 (depends on 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The pharmaceutical composition of any one of claims 28 to 39 for inducing or enhancing an immune response, preferably an immune response against cancer.

### Claim 41 (depends on 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The pharmaceutical composition of any one of claims 28 to 40 for use in a prophylactic and/or therapeutic treatment of a disease involving an antigen, preferably a cancer disease.

### Claim 42 (depends on 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

A method for delivering an antigen to antigen presenting cells, preferably professional antigen presenting cells, in the spleen, or expressing an antigen in antigen presenting cells, preferably professional antigen presenting cells, in the spleen comprising administering to a subject a pharmaceutical composition of any one of claims 28 to 39.

### Claim 43 (depends on 42)

The method of claim 42, wherein the antigen presenting cells are dendritic cells and/or macrophages.

### Claim 44 (depends on 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

A method for inducing or enhancing an immune response, preferably an immune response against cancer, in a subject comprising administering to the subject a pharmaceutical composition of any one of claims 28 to 39.

### Claim 45 (depends on 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

A method for stimulating, priming and/or expanding T cells in a subject comprising administering to the subject a pharmaceutical composition of any one of claims 28 to 39.

### Claim 46 (depends on 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

A method of treating or preventing a disease involving an antigen, preferably a cancer disease, in a subject comprising administering to the subject a pharmaceutical composition of any one of claims 28 to 39.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

A method of producing a particle of any one of claims 1 to 27 comprising the following steps of:
(i) providing a vesicular core having at least one therapeutically effective compound encapsulated therein, and
(ii) adding RNA to the vesicular core, wherein the RNA forms a hydrophilic shell on at least a portion of the vesicular core, thereby forming the particle.

### Claim 48 (depends on 47)

The method of claim 47, wherein the lipid vesicular core to which the RNA is added comprises a liposome comprising at least one cationic lipid.

### Claim 49 (depends on 48)

The method of claim 48, wherein the amount of RNA and the amount of cationic lipids in the liposome is selected such that the net charge formed by the positive charges derived from the cationic lipids and the negative charges derived from the RNA is negative, positive, or zero.

### Claim 50 (depends on 49)

The method of claim 49, wherein the number of positive charges derived from the cationic lipids divided by the number of negative charges derived from the RNA is between 0.025 and 4.
